Tricuspid Regurgitation is Associated with Increased Mortality Independent of Pulmonary Pressures and Right Heart Failure: a Systematic Review and Meta-analysis
Overview
Authors
Affiliations
Aims: To undertake a systematic review and meta-analysis to determine the influence of tricuspid regurgitation (TR) severity on mortality.
Methods And Results: We performed a systematic search for studies reporting clinical outcomes of patients with TR. The primary endpoint was all-cause mortality and secondary endpoints were cardiac mortality and hospitalization for heart failure (HF). Overall risk ratios (RR) and 95% confidence intervals (CIs) were derived for each endpoint according to the severity of TR by meta-analysing the effect estimates of eligible studies. Seventy studies totalling 32 601 patients were included in the analysis, with a mean (±SD) follow-up of 3.2 ± 2.1 years. Moderate/severe TR was associated with a two-fold increased mortality risk compared to no/mild TR (RR 1.95, 95% CI 1.75-2.17). Moderate/severe TR remained associated with higher all-cause mortality among 13 studies which adjusted for systolic pulmonary arterial pressures (RR 1.85, 95% CI 1.44-2.39), and 15 studies, which adjusted for right ventricular (RV) dysfunction (RR 1.78, 95% CI 1.49-2.13). Moderate/severe TR was also associated with increased cardiac mortality (RR 2.56, 95% CI 1.84-3.55) and HF hospitalization (RR 1.73, 95% CI 1.14-2.62). Compared to patients with no TR, patients with mild, moderate, and severe TR had a progressively increased risk of all-cause mortality (RR 1.25, 1.61, and 3.44, respectively; P < 0.001 for trend).
Conclusions: Moderate/severe TR is associated with an increased mortality risk, which appears to be independent of pulmonary pressures and RV dysfunction.
Genske F, Marquetand C, Eitel I, Frerker C, Schmidt T Eur Heart J Case Rep. 2025; 9(2):ytaf066.
PMID: 40008265 PMC: 11851277. DOI: 10.1093/ehjcr/ytaf066.
Lin D, Zou L, Miao J, Fan J, Meng M, Qi Y J Cardiovasc Dev Dis. 2025; 12(2).
PMID: 39997489 PMC: 11856412. DOI: 10.3390/jcdd12020055.
Fortmeier V, Lachmann M, Stolz L, von Stein J, Rommel K, Kassar M JACC Adv. 2025; 4(2):101575.
PMID: 39848099 PMC: 11791227. DOI: 10.1016/j.jacadv.2024.101575.
Lal S JACC Adv. 2025; 4(2):101574.
PMID: 39842178 PMC: 11788718. DOI: 10.1016/j.jacadv.2024.101574.
Interventions for adult congenital heart disease.
Cepas-Guillen P, Flores-Umanzor E, Horlick E, Aboulhosn J, Benson L, Freixa X Nat Rev Cardiol. 2025; .
PMID: 39833478 DOI: 10.1038/s41569-025-01118-1.